Pharmaceutical

UroGen acquires IconOVir’s oncolytic virus assets

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042.

Feb 23, 2025 - 06:00
UroGen acquires IconOVir’s oncolytic virus assets
UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042.
Read the original article

Tags:

Previous Article

Pfizer shelves haemophilia gene therapy Beqvez amid low demand

Next Article

GLP-1 receptor agonists could hold promise for opioid use disorder treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Who’s acquiring who? Immuno-oncology M&A activity in the pharmaceutical industry decreased by 8% in Q1 2023

Who’s acquiring who? Immuno-oncology M&A activity in th...

May 28, 2023

UK rejoins EU’s Horizon Europe science programme

UK rejoins EU’s Horizon Europe science programme

Sep 7, 2023

Datopotamab deruxtecan by Daiichi Sankyo for Peritoneal...

Apr 23, 2024